Skip to main content
. Author manuscript; available in PMC: 2014 Apr 30.
Published in final edited form as: Int J Hematol. 2013 Sep;98(3):275–292. doi: 10.1007/s12185-013-1406-9

Figure 5. Proposed GVHD preemptive clinical study.

Figure 5

Biomarker cutpoints will risk-stratify patients at low- or high-risk of developing GVHD before occurrence of the clinical signs. Low risk patients will have no intervention; high risk patients will be randomized to receive either a standard GVHD intervention or none. Comparison of outcomes from the randomized high risk groups will show whether the preemptive intervention lowers aGVHD incidence in high-risk patients identified by biomarkers. The expectation is that the subclinical aGVHD could be treated, which would defuse the full blown graft-versus-host reaction.